Evidence for the role of GHRH in the regulation of sleep by HASH(0x7fe96c780228)
EVIDENCE FOR THE ROLE OF GHRH IN THE 
REGULATION OF SLEEP
Ph.D. thesis
Dr. Janos Gardi
Endocrine Unit and Department o f Physiology 
Faculty of Medicine, University o f Szeged 
Szeged, Hungary
2005

PAPERS ATTACHED TO THE THESIS
I. Gardi J, Obál F Jr, Fang J, Zhang J, Krueger JM: Diurnal variations and sleep 
deprivation-induced changes in rat hypothalamic GHRH and somatostatin contents.
Am. J. Physiol. (Reg. Jntegr. Comp. Physiol.) 277: R1339-R1344, 1999.
II. Gardi J, Szentirmai É, Hajdú I, Obál F Jr, Krueger J M: The somatostatin analog, 
octreotide, causes accumulation o f growth hormone-releasing hormone and depletion 
of angiotensin in the rat hypothalamus. Neurosci. Lett. 315: 37-40, 2001.
III. Obál F Jr, Fang J, Taishi P, Kacsóh B, Gardi J, Krueger JM: Deficiency o f growth 
hormone-releasing hormone signaling is associated with sleep alterations in the dwarf 
rat. J. Neurosci. 21: 2912-2918, 2001.
IV. Gardi J, Krueger JM, Speth RC: Preparation and a simple one-step purification of  
[His1-mono-125I-Tyrl0,Nle27]-hGHRH(l-32)-NH2. J. Labelled Cpd. Radiopharm. 45: 
13-18, 2002.
V. Gardi J, Speth RC, Taishi P, Kacsóh B, Obál F Jr, Krueger JM: Alterations in GHRH 
binding and GHRH receptor mRNA in the pituitary o f adult dw/dw  rats. Peptides 23: 
1497-1502, 2002.
VI. Gardi J, Taishi P, Speth RC, Obál F Jr, Krueger JM: Sleep loss alters hypothalamic 
growth hormone-releasing hormone receptors in rats. Neurosci. Lett. 329: 69-72,2002.
CONTENTS
ABBREVIATIONS 1
1. INTRODUCTION 2
1.1 GHRH 2
1.2 GHRH receptor 3
1.3 Sleep 5
1.4 The somatotropic axis in sleep regulation 6
1.5 Octreotide 7
1.6 Aims 7
2. METHODS
2.1 Animals 9
2.2 Sleep deprivation 9
2.3 Surgical procedures 9
2.4 Collection o f the brain samples 9
2.5 Determination o f hormones 9
2.6 Radioiodination o f [His‘,Nle27]hGHRH(l-32)NH2 10
2.7 GHRH receptor binding assay 10
2.8 Quantification o f GHRH mRNA and GHRH receptor mRNA 11
2.9 Statistics 11
3. RESULTS
3.1 Diurnal and sleep deprivation-induced variations in GHRH and
somatostatin contents o f the hypothalamus 12
3.2 Effects o f octreotide on hypothalamic GHRH, angiotensin II, and
vasopressin contents 13
3.3 GHRH, GHRH mRNA, GHRH receptor mRNA and GHRH
binding in the GHRH receptor-deficient dwarf rat 14
3.4 Effects o f sleep deprivation on GHRH receptors in the hypothalamus
and in the pituitary 16
4. DISCUSSION
4.1 Sleep-associated variations in hypothalamic GHRH and somatostatin
contents 17
4.2 Effects o f  icv octreotide on GHRH, angiotensin II, and vasopressin
contents o f  the hypothalamus 18
4.3 GHRH signaling in dw/dw  rats 20
4.4 Effects o f sleep deprivation on hypothalamic and pituitary GHRH receptors 21
CONCLUSIONS 23
SUMMARY 24
REFERENCES 26
ACKNOWLEDGEMENTS 37
APPENDIX 38
ANOVA
cAMP
cDNA
EEG
GABA
GH
GHRH
GPCR
HPLC
icv
IGF-I
mRNA
NREMS
REMS
RT-PCR
sstl-5
TMD
VIP
ABBREVIATIONS
Analysis o f Variance
Cyclic Adenosine-Monophosphate
Complementary Desoxi-Ribonucleic Acid
Electroencephalogram
y-Amino-Butyric Acid
Growth Hormone
Growth Hormone-Releasing Hormone
G-Protein Coupled Receptor
High Pressure Liquid Chromatography
Intracerebroventricular
Insulin Like Growth Factor-1
Messenger Ribonucleic Acid
Non-Rapid Eye Movement Sleep
Rapid Eye Movement Sleep
Reverse Transcription-Polymerase Chain Reaction
Somatostatin Receptor 1-5
Transmembrane Domain
Vasoactive Intestinal Peptide
1. INTRODUCTION
GH is synthesized, stored, and secreted by the pituitary somatotrophs. Its secretion is pulsatile 
in nature. In man, secretory bursts o f the hormone occur 4 to 8 times over a 24-h period, with 
maximal secretion occuring within 1 h after the onset o f sleep. Pulsatile secretion o f the 
hormone is believed to be important as regards the physiological action on target tissues. The 
synthesis and secretion o f GH from pituitary somatotroph cells is tightly regulated by several 
factors, including neurotransmitters such as GABA, neuropeptide Y, peptide hormones such 
as ghrelin and IGF-I, steroid hormones, and the opioids (1-5). Hypothalamic GHRH and 
somatostatin are the predominant stimulatory and inhibitory neuroendocrine signals, 
respectively, for GH secretion by pituitary somatotroph cells (6,7). GHRH stimulates GH 
secretion and GH synthesis and also promotes somatotroph proliferation (8,9). Somatostatin 
acts on the pituitary to suppress basal and stimulated GH secretion (10). Each GH secretory 
episode seems to be initiated by a burst o f GHRH release into the hypophyseal portal system, 
preceded by a reduction o f somatostatinergic input both to the pituitary portal circulation and 
to hypothalamic GHRH neurons (11).
1.1 GHRH
GHRH was first isolated from human pancreatic tumors by Guillemin et al. (12) and by Rivier 
et al. (13) in two forms, as GHRH(1-40)-OH and GHRH(l-44)-NH2 polypeptides. Both 
variants are generated from the same precursor (prepro-GHRH), with the full biological 
activity residing in the first 29 amino acids (14). This 29-residue core has an a-helical 
conformation (15), and enhancement o f the amphipathic a-helical properties o f GHRH by 
alanine replacement results in an increased receptor affinity and potency demonstrated in vitro 
(16). The mature peptide is amidated at the carboxy-terminus in many species, but not in 
rodents. Hypothalamic and pancreatic GHRH appear to be identical. GHRH belongs to the 
secretin-glucagon peptide family displaying structural homology with secretin, pituitary 
adenylate cyclase-activating peptide, VIP, glucagon, glucagonlike peptide-1, gastric 
inhibitory peptide, and peptide histidine isoleucine/peptide histidine methionine (17). GHRH 
shares nine residues with VIP, with the greatest similarities occuring in the N-terminal regions 
of the peptide. The structure o f human pancreatic GHRH is
Tyr-Ala-Asp-Ala-Ile-Phe-Tyr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-
Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-
Ala-Arg-Leu-NH2
In addition to its GH-releasing activity, GHRH is implicated in the control o f appetite (18), 
and sleep (19,20).
Most GHRH containing neurons are found in the arcuate nucleus o f the hypothalamus and the 
pituitary stalk, but neurons o f the periventricular area and paraventricular nucleus also contain 
significant amounts o f GHRH. Axons o f GHRH neurons o f the the arcuate nucleus project to 
the median eminence and terminate near the capillaries o f the primary capillary plexus that in 
turn is drained by pituitary portal circulation. Release o f GHRH into the portal vessels is 
episodic, contributing to the pulsatile release o f GH from the pituitary. GHRH containing 
perikarya found in the ventromedial nuclei and extrahypothalamic structures do not project to 
the median eminence but to several other hypothalamic and extrahypothalamic regions, 
suggesting a possible neuromodulator role o f GHRH in the central nervous system. In 
addition, GHRH has been found in the placenta (21,22), where it might participate in the 
regulation of fetal GH secretion and is expressed in ovary (23) and testis (24), possibly acting 
as an intragonadal regulatory factor (25,26). It has been detected in lymphocytes, where it 
may be involved in immune modulation (27), and in the pancreas and the gastrointestinal tract 
(28,29), where it possibly regulates the secretion o f hormones from both the exocrine and 
endocrine pancreas (30-32).
1.2 GHRH receptor
GHRH receptor expressed predominantly in the anterior pituitary gland, as expected on the 
basis o f its functional role in the regulation o f GH secretion. Specific high-affinity binding 
sites for GHRH have been demonstrated on pituitary membranes using various iodinated 
GHRH analogs (33-36). This binding was inhibited by guanine nucleotides, suggesting that 
G-proteins were involved in GHRH action (37). These observations and the finding that 
cAMP is a key second messenger for GHRH action, suggested that the actions o f GHRH were 
mediated through a GPCR.
GHRH receptor cDNAs from rat (38,39), mouse (38), swine (40), and humans (39,41) have 
been identified. The amino acid alignment deduced from the human cDNA revealed that the 
GHRH receptor consists o f 423 amino acids containing seven hydrophobic domains with the
potential to serve as membrane-spanning helices. The mouse and rat receptors share 94% 
identity at the amino acid level and both o f these are 82% identical to the human receptor. The 
protein has a signal sequence and seven TMDs, with a 127-residue-long extension upstream 
of the first TMD predicted to form an amino-terminal extracellular domain. In addition to the 
presence o f seven TMDs, the predicted GHRH receptor protein has other characteristic 
features o f GPCR, including conserved cysteine residues in the first and second extracellular 
loops, a cysteine residue in the C-terminal tail that may be palmitoylated, a site for N-linked 
glycolisation sites in the amino-terminal domain, potential phosphorylation sites in the third 
intracellular loop, and several residues within the TMDs that are highly conserved among all 
GPRCs. The GHRH receptor has a high degree o f homology to the receptors for GHRH- 
related peptide hormones including secretin, VIP, glucagon, glucagonlike peptide-1, pituitary 
adenylate cyclase-activating peptide, and gastric inhibitory peptide receptors, all o f which are 
classified into family B-III o f the GPCR superfamily (42). These receptors exhibit a high 
degree o f overall homology, which is highest in the TMDs, and share several distinct 
structural features, including six cysteines, an aspartate, a trypthophan, and a glycin in the 
amino-terminal domain that are highly conserved among all the receptors. These receptors are 
more distantly related to the receptors for parathyroid hormone, calcitonin, and corticotropin­
releasing factor, which are also classified into family B o f the GPCR superfamily.
In response to GHRH, the GHRH receptor activates adenylate cyclase, resulting in an increase 
in intracellular cAMP levels (39). It leads to stimulation o f the cAMP-dependent protein 
kinase A, which in turn phosphorylates numerous cytoplasmic and nuclear substrates (43). 
One o f the best characterized protein kinase A nuclear substrates is the transcription factor 
CREB (cAMP-responsive element binding protein), which stimulates transcription o f cAMP- 
responsive genes after its phosphorylation by protein kinase A (44). GHRH does not stimulate 
phosphoinositide breakdown in primary pituitary cells (45,46), suggesting that the receptor 
does not couple to the phospholipase C pathway. In addition to stimulating the adenylate 
cyclase pathway, GHRH also activates the mitogen-activated protein kinase pathway in both 
pituitary cells (47,48) as well as in nonpituitary cells expressing the GHRH receptor (49). 
Activation o f the mitogen-activated protein kinase pathway likely mediates the mitogenic 
activity o f GHRH in somatotroph cells (48).
The GHRH receptor mRNA is expressed predominantly in the pituitary gland, can be detected 
begining with the late embryonic period, and restricted to the anterior lobe of the gland
(38,39). GHRH receptor mRNA has also been found in the placenta (50), the kidney (50,51), 
and the hypothalamus (52). Using sensitive RT-PCR/Southem blotting assays, the GHRH 
receptor transcript has been found in an extremely wide range o f rat tissues at low levels (51) 
although the physiological significance o f this broad expression remains unclear. GHRH 
receptor-immunoreactive protein has been demonstrated only in the pituitary and the kidney
(53.54) .
Several isoforms o f the GHRH receptor have been identified in species including the mouse
(38.55) , rat (39,52,55), pig (40), and human (56-59).
1.3 Sleep
Rest-activity rhythms are displayed by each species throughout the animal kingdom. In 
mammals, two states o f sleep are distinguished: REMS and NREMS. The states o f sleep are 
fundamentally different in terms o f regulation and EEG activity. The structures involved in 
the generation o f REMS reside in the brainstem. In contrast, forebrain structures (anterior 
hypothalamus/preoptic region, thalamus) have been implicated in the genesis o f NREMS. 
These areas o f the forebrain are the origin o f projection pathways that synchronize the 
activities o f distant parts o f the brain. Otherwise, the regulation o f NREMS might be local 
(60). Periods o f REMS and NREMS alternate during sleep. Besides the duration, NREMS has 
another measure: intensity (depth o f NREMS). The intensity o f NREMS is characterized 
quantitavely by the slow wave activity in the EEG. Deep NREMS with intense slow wave 
activity is observed during the first sleep cycles o f the diurnal rest period. The duration o f  
REMS epochs increases towards the end o f sleep resulting in an increased time spent in 
REMS in the second part o f the rest period. These principles o f sleep organization are easily 
recognized in each species with a strong circadian rhythm. Thus, in spite o f the phases o f the 
rest period are different in humans and rats (rats are active at night), there is a high degree of 
similarity in the organization and regulation o f sleep between these species (61).
Secretions o f many hormones vary in synchrony with sleep-wake activity. These variations 
are, however, not linked to sleep. Sleep exhibits circadian rhythm and the circadian 
pacemaker may also modulate hormone production and/or release. That variations in hormone 
secretions are in fact associated with sleep or they are subject to circadian regulation can be 
distinguished by means o f sleep deprivation. Currently, the biological significance o f sleep- 
associated alterations in hormone secretions is not clear. On the one hand, these changes in 
hormone release may have importance for endocrinology. On the other hand, hormones may
act as sleep-promoting or arousing substances and might be involved in the regulation o f 
sleep-wake activity.
1.4 The somatotropic axis in sleep regulation
Pituitary GH secretion is stimulated by hypothalamic GHRH and is inhibited by somatostatin. 
GH acts in part directly and in part indirectly via IGF-I in the tissues. IGF-I is both a 
paracrine/autocrine produced locally and a hormone released from the liver in response to 
GH. There are also various negative feedback loops in the somatotropic axis. The 
somatotropic axis is a major humoral mechanism regulating sleep-wake activity. Deep 
NREMS is associated with GH secretion (62). GHRH promotes sleep, particularly NREMS in 
both animals (19,20,63) and humans (64-66). GHRH enhances both the duration and the 
intensity (slow wave activity o f the EEG) o f NREMS. This is a hypothalamic action of 
GHRH and independent from the stimulation o f GH secretion since hypophysectomy does not 
block promotion o f NREMS by exogenous GHRH (67). Independently from GHRH, GH may 
increase the intensity o f  NREMS (68) and the duration o f REMS (69-71). NREMS decreases 
when GHRH is inhibited by means o f a competitive receptor antagonist (72) or by the 
activation o f the negative feedback in the somatotropic axis, e.g., after high doses o f GH (71), 
IGF-I (73), or after somatostatinergic stimulation (74,75). Hypothalamic GHRH mRNA 
content varies with sleep-wake activity (76). Sleep deprivation stimulates GHRH synthesis 
(77,78), and GHRH is involved in the mediation o f the enhancements in sleep following sleep 
deprivation (79). Microinjection o f GHRH into the medial preoptic region is followed by 
large increases in NREMS whereas GHRH antagonist administered into the same area inhibits 
NREMS (80). The preoptic region is known to be involved in sleep regulation (81), and it is 
also receives projections from extraarcuate GHRHergic neurons (82). It is assumed, therefore, 
that the preoptic region is the NREM-specific somnogenic action site o f GHRH. GHRH 
applied into the preoptic region fails to alter REMS (80). Stimulation o f REMS is regarded as 
an indirect effect o f GHRH involving GH (67).
In addition to GHRH, other members o f the somatotropic axis may also modulate sleep. 
Acute administration o f GH elicits increases in REMS in humans (71), rats (69), and cats 
(70). IGF-I may promote NREMS (83), and somatostatin may stimulate REMS (84,85). In 
addition, acute rises in somatostatin, GH, and IGF-I can suppress sleep via negative feedback 
inhibition o f GHRH (71,73-75). Somatostatin inhibits GHRHergic neurons in the 
hypothalamus, and thereby it may also decrease NREMS. Somatostatin modulates the activity
of the somatotropic axis in multiple ways. It is delivered to the pituitary gland by the blood 
where it inhibits GH secretion. Somatostatin also inhibits GHRH-containing neurons in both 
the arcuate nucleus and the median eminence. Five somatostatin receptors have been 
determined in the brain (sstl-5). Inhibition o f the somatotropic system is attributed to the sst2 
receptors (86).
1.5 Octreotide
The sequence o f octreotide is as follows: DPhe-Cys-Phe-DTrp-Lys-Thr-Cys-Thr(ol) (87). The 
advantage of using octreotide instead o f somatostatin is that octreotide is 20 to 75-fold more 
potent than somatostatin in inhibiting GH secretion, and it is highly resistant to enzymatic 
breakdown. Somatostatin is eliminated in a few minutes whereas the half-life o f octreotide is 
45-110 min in the tissues (88). Octreotide is a strong agonist on the sst2 and sst5 receptors, 
displays a modest affinity to sst3 receptors, and does not bind to sstl and sst4 recpetors (89).
Previous experiments in our laboratory indicate that icv administered octreotide induces 
prompt drinking, vasopressin secretion and rises in blood pressure (75,90). It is well- 
documented that icv. administration o f angiotensin II elicits the same triple response (91). 
Inhibition o f the angiotensin convertase I-enzyme by captropil blocks the octreotide-induced 
responses (90). It is likely therefore, that octreotide acts via the central angiotensinergic 
system. Octreotide also alters sleep: octreotide injection elicits an immediate suppression in 
NREMS followed by enhancements in EEG slow wave activity starting 2 to 3 h post­
injection. (75,85). These sleep changes correlate with the effects o f  octreotide on GH- 
secretion: octreotide causes prompt inhibition o f GH-secretion, and GH-secretion recovers 
when sleep time is normalized and enhanced slow wave activity is observed in the EEG. It is 
hypothesized that inhibition o f GHRH by octreotide is the cause o f the immediate sleep 
suppression whereas the late enhancements in deep NREMS result from an increased GHRH- 
activity as the inhibition vanishes.
1.6 Aims
The experiments reported herein were carried out in rats with the following specific aims:
1. To study sleep-associated changes in hypothalamic GHRH and somatostatin contents 
(Paper #1),
2. To analyze changes in hypothalamic GHRH-, angiotensin II-, and vasopressin-content after 
somatostatinergic stimulation (Paper #2),
3. To characterize GHRH-R mRNA levels and GHRH content o f the hypothamus, and its 
relationship to spontaneous sleep in chronic somatotropic deficiency (Paper #3),
4. To develope a simple, alternative method to label a GHRH analog with 125I, and 
demonstrating o f its utility in a binding assay for GHRH receptors (Paper #4),
5. To characterize GHRH receptor binding and mRNA in the pituitary o f dwarf (dtw/dw) and 
normal Lewis rats (Paper #5),
6. To study the effects o f  sleep deprivation on GHRH receptors in the hypothalamus and in 
the pituitary (Paper #6).
The experiments, including the methods, results and discussion o f the data are detailed in the 
published Papers attached.
2. METHODS
2.1 Animals
Adult male outbred Sprague-Dawley rats (body weights 300-320 g), or adult male 
(approximately 4-month-old) inbred normal Lewis and dw/dw Lewis rats were used in the 
experiments. The rats were housed in individual cages. The cages were placed in recording 
rooms with a 12:12 h light-dark cycle and with an ambient temperature 26 ± 1 °C. The rooms 
were sound attenuated. The rats were kept in conditions identical to those in the recording 
rooms for at least 1-2 weeks before the experiments. Food and water were continously 
available.
2.2 Sleep deprivation
In the experiments with sleep deprivation, the rats were sleep deprived by gentle handling 
starting at light onset while the rats stayed in their home cage. Whenever behavioral signs of 
sleep were observed, the rats were aroused by knocking on the cage or touching them.
2.3 Surgical procedures
Surgery was carried out under ketamine-xylazine (87 and 13 mg/kg, respectively) anaesthesia. 
An icv cannula was implanted into the left cerebral ventricle [0.80 mm posterior from 
bregma, 1.4 mm lateral from midline, and 3.5 mm caudal from the top o f the skull according 
to the rat brain atlas by Paxinos and Watson (92)].
2.4 Collection o f  the brain samples
The rats were sacrificed with a guillotine. The hypothalamus (landmarks: optic chiasma, 
lateral sulci, mamillary bodies, and depth o f 2 mm) and/or the hypophysis was removed 
within 1 min and stored -70 °C until assayed.
2.5 Determination o f  hormones
The frozen samples were weighed. For extraction, samples were boiled for 5 min in 0.5 ml 
2M acetic acid. The tissues were individually homogenized by means o f ultrasound. The 
homogenates were centrifuged at 15000 g for 20 min at 4 °C, aliquots were taken for protein 
measurement (93), and the rest o f  each supernatant was lyophilized for the assays.
GHRH, somatostatin, and vasopressin were determined by radioimmunoassay 
(Bachem/Peninsula Laboratories, San Carlos, CA, USA) whereas angiotensin-II was
✓
measured by enzyme immunometric assay (SPI-BIO, France). The peptides were measured in 
duplicate or triplicate with a sensitivity o f 8 pg/tube for GHRH, 4 pg/tube for somatostatin, 1 
pg/tube for vasopressin and 0.2 pg/well for angiotensin-II. The intra- and interassay 
coefficients o f variation were less than 12 % for each assay.
2.6 Radioiodination o f  [His1, Nle27]-hGHRH(l-32)-NH2
The chloramine-T method (94) was used for iodination o f the GHRH analog. Two-hundred 
microliters o f 500 mM sodium phosphate buffer (pH = 7.4), 25 pi synthetic [His1, Nle27]- 
hGHRH(l-32)-NH2 (1.5 mg/ml), 20 pi Na125I (360 pCi/pl), 20 pi chloramine-T were added 
into a tube successively. After mixing for 20 s at room temperature the labeling reaction was 
terminated by addition o f 30 pi o f Na2S20s (5 mg/ml), with continued mixing for 20 s. The 
mixture was loaded onto the chromatographic column.
[His1, 125I-Tyr10, Nle27]hGHRH(l-32)amide was separated from unreacted 125I and [His1, 
Nle27]hGHRH(l-32)amide by reverse phase (Cig) HPLC with isocratic elution at a flow rate 
of 1.6 ml/min. The mobile phase was 30 % acetonitrile and 70 % triethylamine phosphate 
(166 mM phosphate, pH = 2.35).
2.7 GHRH receptor binding assay
For the binding assay, pituitary or hypothalamic samples were immediately harvested and 
were pooled from 2 to 4 rats to obtain one assay sample.
The GHRH analog [His1, 125I-Tyr10, Nle27]hGHRH(l-32)amide was used as the radioligand in 
the binding assay. The samples were weighed and then were homogenized in ice-cold assay 
buffer (50 mM Tris, 5 mM MgCh, 0.24 M sucrose, 2 mM EDTA, 2 mg/ml BSA, pH 7.4 for 
the pituitary or 6.5 for the hypothalamus). 100 pi aliquots were added to tubes containing 50 
pi o f assay buffer containing the radioligand at different concentrations ranging from 50 to 
600 pM. After incubation for 1 h at room temperature, the mixture was transferred to a 
siliconized microcentrifuge tube and centrifuged for 2 min at approximately 13600 g. The 
supernatant was aspirated, the bottom o f the microcentrifuge tube containing the tissue 
membrane pellet was chopped off, placed into a fresh tube, and the radioactivity was 
measured. Nonspecific binding was determined in half o f the tubes with the addition 2 x 10'7 
M o f unlabeled GHRH analog. Nonspecific binding was subtracted from total binding to 
obtain specific binding.
In competition experiments, membrane homogenates were incubated with approximately 500 
pM [His1, 125I-Tyr10, Nle27]hGHRH(l-32)amide and different concentrations (10'10 -  10'6 M) 
of nonradioactive analogs and other peptides.
The binding data were evaluated by computerized nonlinear regression analysis (PRISM, 
Graphpad Software, San Diego, CA, USA).
2.8 Quantification o f  GHRH mRNA and GHRH receptor mRNA
RT-PCR was used to determine GHRH mRNA and GHRH receptor mRNA levels. Total 
RNA was extracted from the tissues using RNA STAT-60 or Trizol reagent. Extracted RNA 
was characterized by formaldehide-containing agarose electrophoresis and by absorbance at 
260 nm. First-stranded cDNA was synthesized with oligo-dT priming and Supercript II RNase 
reverse transcriptase from each sample. The cDNA was amplified by PCR. A detailed 
description o f the RT-PCR procedures can be found in the Papers (#3, #5, #6) attached.
2.9 Statistics
The tests used included Student’s t-test, one-way and two-way ANOVA, Student-Newman- 
Keuls test, and Pearson Correleation test. An alpha-level o f  P < 0.05 was considered to be 
significant in all tests.
Statistics are listed in detail in the Papers attached.
3. RESULTS
3.1 Diurnal and sleep deprivation-induced variations in GHRH and somatostatin contents o f  
the hypothalamus
To study the diurnal rhythm in hypothalamic peptide content the rats were killed at 4-h 
intervals starting 1 h after light onset. In the experiment with sleep loss, sleep deprivation 
started at light onset. Hypothalamic samples were obtained after 4 and 8 h o f sleep 
deprivation and after 1 and 2 h o f recovery following 8 h o f sleep deprivation. The time- 
matched controls were undisturbed and used for the determination o f the diurnal rhythms of 
the peptides.
GHRH: Hypothalamic GHRH content displayed significant diurnal variations (Fig. 1.) with 
low levels in the morning followed by a transient rise at 1 h after light onset, and then GHRH 
dropped to a minimum occuring by the middle o f the day. GHRH content increased gradually 
in the afternoon. Peak values occured at the end of the light period and at the beginning of the 
dark period. GHRH decreased during the night. The mean GHRH values during the 12-h light 
and 12-h dark periods did not differ.
Sleep deprivation induced significant depletion o f hypothalmic GHRH content (Fig. 1.). 
GHRH was normal after 4 h o f SD and dropped to a low level by the end o f hour 8 o f SD. 
GHRH was significantly suppressed after 1 h o f recovery. Althought GHRH content started to 
rise by the end o f hour 2 o f recovery it was still significantly below normal.
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Fig. 1. Diurnal ( •  and lines) and sleep deprivation (SD)-induced (bars) variations in hypothalamic GHRH 
content (means ± SE). Diurnal rhythm is double plotted, and effects o f  SD are shown on day 2. Periods between 
hour 0 and hour 12, as well as hour 24 to hour 36 are light periods. Dark periods are marked by horizontal bars. 
SD started at light onset (hour 24) and lasted for 8 h (hour 32), as indicated by arrows. GHRH was determined 
after 4 and 8 h o f  SD, and after 1 and 2 h o f  recovery (R) after deprivation.
Somatostatin: Hypothalamic somatostatin content also varied significantly across the 24-h 
day (Fig. 2.). The patterns o f the diurnal variations in GHRH and somatostatin content o f the 
hypothalamus were similar, but there was no significant correlation between them. The 
afternoon rise was delayed, and the nocturnal decline o f somatostatin was more rapid than the 
changes in GHRH. Mean somatostatin contents during the light period were significantly 
lower than at night.
SD did not alter somatostatin significantly (Fig. 2.). Correlations were not found between 
somatostatin contents and variations in GHRH during and after SD.
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Fig. 2. Diurnal ( •  and lines) and sleep deprivation (SD)-induced (bars) variations in hypothalamic somatostatin
content (means ± SE). See Fig. 1. for additional data.
3.2 Effects o f  octreotide on hypothalmic GHRH, angiotensin-II, and vasopressin contents 
One group of rats was injected icv with 0.1 pg octreotide in a volume o f 2 pi. The other group 
received 2 pi vehicle in the same dilution as the octreotide solution. The vehicle containing 
lactate and mannitol was donated by Novartis. The injections were performed at light onset. 
Hypothalamic samples were collected 10 min, 1,3, and 6 h post-injection.
Icv injection o f octreotide caused significant changes in GHRH content o f the hypothalamus 
compared to control values obtained in rats injected with the vehicle (Fig. 3.). A tendency to 
GHRH accumulation was obvious after 10 min but the differences reached statistical 
significance only at hour 1 post-injection. At that time point, hypothalamic GHRH content 
was 30% higher in rats injected with octreotide than in the controls. GHRH content started to 
decline between hours 1 and 3 post-injection and this process continued until hour 6.
Hypothalamic angiotensin II content differed significantly between the rats injected with the 
vehicle and octreotide, and the difference varied with time (Fig. 3.). lev octreotide elicited a 
prompt drop in the angiotensin II content o f the hypothalamus. The angiotensin content 
decreased by about 27% 10 min after injection. It was still below the control values 1 h after 
injection but these changes were not significant. Thereafter, angiotensin II content returned to 
normal at hour 3 and increased above baseline at 6 h post-injection. The difference at hour 6 
was not significant between the two groups.
Fig. 3. Changes in hypothalamic GHRH and angiotensin II contents after iev injection o f octreotide. Mean ± SE,
% deviation from values after injection o f the vehicle.
Arrow: injection (time 0); Asterisk: significant difference.
Vasopressin contents o f the hypothalamus were not altered siginificantly after octreotide. The 
values obtained 1 and 3 h after iev octreotide tended to be slightly lower than the vasopressin 
contents in the controls but these changes did not reach the level o f statistical significance. 
Vasopressin in the pituitary was also measured. Though these sample sizes were too low for 
statistical analysis, the vasopressin content o f the pituitary harvested 10 min after treatment 
was lower in each o f the rats which received octreotide than any o f the rats injected with 
vehicle. There were no differences among the groups in the vasopressin content o f the 
pituitary 1, 3, or 6 h post-injection.
3.3 GHRH, GHRH mRNA, GHRH receptor mRNA, and GHRH binding in the GHRH 
receptor-deficient dw arf rat
The mutant Lewis dwarf (dw/dw) rat exhibits GH deficiency and growth retardation which are 
linked to a malfunction o f GHRH signaling. In adult dw/dw rats, plasma concentrations of 
GH, GH content o f the pituitary, and GH and cAMP responses to GHRH are greatly
decreased (95,96). GHRH receptor mRNA levels are reduced in the pituitary o f dw/dw rats 
(97).
Levels o f GHRH mRNA and GHRH receptor mRNA as well as GHRH contents were 
measured in the hypothalamus/preoptic region, whereas GHRH binding and levels o f the short 
isoform of GHRH receptor mRNA were determined in the pituitary.
Although hypothalamic GHRH mRNA levels were normal, GHRH peptide content in the 
hypothalamus of the dw/dw  rats was only one-half o f that found in normal Lewis rats. This 
difference between the two groups was statistically significant. Expression o f the short 
isoform of GHRH receptor mRNA was decreased in the hypothalamus/preoptic region.
The binding o f 125I-GHRH analog to the pituitary of normal Lewis rats was specific and 
saturable (Fig. 4.).
Fig. 4. [His1, l25l-Tyrl0,Nle27]hGHRH( 1-32) amide binding to pituitary membranes prepeared from normal Lewis
rats.
Saturable GHRH binding was undetectable in eight o f nine pools o f pituitaries harvested from 
the dw/dw rats. Small specific binding was obtained in one o f the pools (Table).
Table
GHRH binding parameters (mean ± SE) in pituitary membrane preparations.
Kd: dissociation constant; Bmax: receptor density
+ Specific binding was observed in only one out o f nine pools o f  pituitaries obtained from dw/dw rats, so there is 
no SE for Kd and Bmax in this group.
Group Kd (pM) Bmax (fmol/mg protein Bmax (fmol/mg tissue)
Lewis (n=10) 241 ±34 .0 22.4 ± 2.60 2.4 ± 0.25
dw/dw (n=l out o f 9)+ 126 4.3 0.4
The specificity o f GHRH binding was demonstrated by diplacement experiments using 
several peptides. The binding o f 125I-GHRH analog was inhibited by increasing 
concentrations o f rat GHRH and human analogs.
GHRH receptor mRNA was detectable in all dw/dw pituitaries examined, averaging 21% that 
o f normal Lewis rats.
3.4 Effects o f  sleep deprivation on GHRH receptors in the hypothalamus and in the pituitary 
Hypothalamic and pituitary GHRH binding and GHRH receptor mRNA were determined in 
Sprague-Dawley rats at the termination o f an 8-h sleep deprivation and after 2 h o f recovery 
following sleep deprivation. Control samples were collected from undisturbed rats at a time 
point corresponding to the termination o f sleep deprivation, and at the time point 
corresponding to sleep deprivation + 2 h recovery.
The characteristics o f the hypothalamic GHRH binding sites differed from those o f the 
pituitary. The affinity o f the radioligand was much higher for the pituitary membranes (IQ: 
3.21 ± 0.641 nM for hypothalamus; IQ: 0.16 ± 0.017 for pituitary). In the hypothalamus, 
GHRH binding levels decreased by 50% after sleep deprivation and after 2 h recovery. In 
contrast, maximal binding in the pituitary did not change after sleep deprivation. The affinities 
of the hypothalamic and pituitary binding sites for the radioligand remained unaltered after 
sleep deprivation or after recovery as compared to the time-matched controls.
The binding o f the radioligand was inhibited by increasing concentrations o f rat GHRH(l-43) 
and by human GHRH analogs in both the pituitary and the hypothalamic samples. Vasoactive 
intestinal peptide did not compete with the 125I-GHRH analog in the pituitary membrane 
preparations at a concentration as high as 1 pM. In contrast, the IC50 o f VIP (24.69 nM) to 
hypothalamic GHRH binding sites was in the same range as that o f the rat GHRH (14.15 nM). 
Hypothalamic GHRH receptor mRNA levels significantly decreased in the sleep-deprived rats 
compared to controls. In contrast, pituitary GHRH receptor mRNA levels did not differ 
between the two groups.
4. DISCUSSION
4.1 Sleep-associated variations in hypothalamic GHRH and somatostatin contents
Our results demonstrate diurnal variations and sleep deprivation-induced changes in
hypothalamic GHRH content.
Although the kinetics o f translation, and those o f peptide release, degradation and elimination 
are not known, comparison between GHRH mRNA levels and peptide contents may allow 
some reasonable conclusions. Hypothalamic GHRH mRNA peaks around light onset, declines 
gradually throughout the light period, and stays at very low levels at night (76). Therefore, the 
transient rise in GHRH content in the morning may indicate synthesis o f the peptide. In our 
previous mRNA studies, samples were taken 3 h before light onset and 1 h after light onset. 
Peak o f GHRH mRNA occured 1 h after light onset. An instantaneous translation is unlikely. 
It is assumed therefore that peak transcription occurs 1 to 2 h earlier than the transient rise in 
peptide content. The finding that hypothalamic GHRH mRNA is already enhanced at light 
onset (77) supports this interpretation. A 1- to 2-h interval between the increases in GHRH 
mRNA and peptide contents corresponds to the kinetics o f translation o f GHRH in the arcuate 
nucleus (98). The drop in GHRH content after the morning peak indicates a rapid release 
exceeding the rate o f synthesis until mid-day. The rise in GHRH content at the end o f the light 
period is attributed to a combination o f a continual peptide synthesis and a low rate o f release. 
The decline in GHRH content at night may result from a release or degradation with 
disproportionately low rate o f synthesis as indicated by the low level o f GHRH mRNA.
Hypothalamic GHRH mRNA increased after sleep deprivation starting at light onset and 
lasting for 6 (77), 8, or 12 h (78). GHRH content decreases significantly by the end o f an 8-h 
sleep deprivation, and stays low for 1 to 2 h o f recovery. Considering that GHRH mRNA is 
already higher than normal at least 2 h before the termination o f the 8-h sleep deprivation then 
the low postdeprivation peptide content may occur in the face o f a high rate o f synthesis. 
Taken together, it suggest an intense hypothalamic GHRH release. Unfortunately, it is not 
known whether translation is altered during sleep deprivation. Stimulation o f transcription 
during sleep deprivation may be a regulatory response to the depletion o f GHRH sometime 
between hour 4 when the GHRH content is normal and hour 6 when GHRH mRNA is already 
enhanced.
In rats, the duration and the intensity o f NREMS peak at the beginning o f the light period. 
Both o f these parameters o f NREMS decline towards dark onset (99-101). The sleep 
deprivation protocol used in our experiments induces recovery sleep with intense NREMS for 
a few hours (102). Therefore, the periods o f increased in GHRH release and synthesis, the 
first portion o f the light period and recovery after sleep deprivation, correlate with the period 
of most intense NREMS. If depletion o f hypothalamic GHRH indicates GHRH release at 
night and during sleep deprivation then GHRH may be part o f the homeostatic process 
responsible for somnolence.
Considering the opposite effects o f GHRH and somatostatin on both GH secretion and sleep, 
it was an attractive idea to determine both peptides from the same hypothalamic samples. 
Unlike GHRH, however, somatostatin is a pleiotropic neurotransmitter in intemeurons 
involved in many functions throughout the hypothalamus (103). Sleep deprivation did not 
alter somatostatin significantly, although somatostatin displayed diurnal variations. 
Previously, Nicholson et al. (104) reported that hypothalamic somatostatin content declines 
during the first portion o f the light period. Berelowitz et al. (105) described progressive in 
vitro somatostatin release during the light period in hypothalamic samples obtained at various 
time points. Somatostatin concentrations in the cerebrospinal fluid and in hypothalamic portal 
vessels are higher at night than during the day (106). The large drop in somatostatin content of 
the hypothalamus might reflect this enhanced release. The diurnal rhythm o f somatostatin 
content in our hypothalamic samples differed from the variations in somatostatin in the 
suprachiasmatic nucleus (107) or the anterior hypothalamus, which includes the 
periventricular area (108). Our results do not exclude the possibility that somatostatin also 
contributes to sleep regulation. Somatostatinergic stimulation alters sleep (85), and there are 
reciprocal changes in the somatostatin and GHRH mRNA levels in the hypothalamus in 
response to sleep deprivation (78). Our data, however, show that hypothalamic somatostatin 
contents cannot be simply linked to the activity o f the somatotropic axis or sleep without 
reference to specific nuclei.
4.2 Effects o f  icv octreotide on GHRH, angiotensin II, and vasopressin contents o f  the 
hypothalamus
The GHRH content o f the hypothalamus increased significantly after icv administered 
octreotide. This immediate accumulation o f GHRH in the hypothalamus may indicate either 
an increase in synthesis or an inhibition o f release. Interpretation o f GHRH accumulation in
vivo as a sign of release inhibition by octreotide is in agreement with previous in vitro data 
demonstrating inhibition o f GHRH release by somatostatin (109). Histological observations 
indicate that a subgroup o f GHRH-containing neurons expresses somatostatin receptors and is 
innervated by somatostatinergic fibers (110,111). Some o f these somatostatinergic neurons 
project to and inhibit GHRH-containing neurons via sst2 type somatostatin receptors (112). 
Octreotide is a potent agonist on sst2 and sst5 receptors (86). Our results suggest that 
stimulation o f sst2 receptors inhibits GHRH release and icv-administered octreotide reaches 
the sst2 receptors mediating this action. GHRH promotes the duration and the intensity o f 
NREMS, and suppression o f endogenous GHRH actions by means o f immunoneutralization 
o f GHRH (79) or by means o f a competitive antagonist (72) is followed by decreases in 
duration and intensity o f  NREMS. Inhibition o f GHRH release may explain the octreotide- 
induced suppression o f sleep reported previously. Our data also show that the GHRH 
accumulated upon exposure to octreotide was gradually released 1 h post-injection. This 
excess GHRH may mediate the enhancements in the intensity o f NREMS observed during 
this period (75).
lev somatostatinergic stimulation by octreotide elicits prompt and excessive decreases in 
hypothalamic angiotensin II content. The depletion o f angiotensin II suggests a release o f the 
peptide from the the hypothalamus. Somatostatin-induced vasopressin secretion and rises in 
blood pressure were previously reported in the literature. By using octreotide, experiments in 
our laboratory supported these findings and revealed that iev administration o f octreotide also 
induces characteristic behavioural responses (75). 1-2 min post-injection the rats start 
drinking, and water consumption lasts 6-10 min. Drinking is followed by scratching, 
grooming and eating (113). Drinking, vasopressin release and increase in blood pressure are 
well-documented responses to iev administration o f angiotensin II. Hence, octreotide elicits 
the same triple response as angiotensin II does. lev injection o f the angiotensin I-converting 
enzyme inhibitor, captopril, and the angiotensin receptor antagonists, saralasin and losartan, 
inhibit octreotide-induced drinking, vasopressin secretion and rises in blood pressure (75). 
These observations suggest that intracerebral angiotensin II either has a permessive role, or 
mediates, octreotide-induced drinking and vasopressin secretion. Somatostatin is an inhibitory 
neurotransmitter and, therefore, it cannot directly stimulate angiotensinergic neurons. In 
agreement with the notion that somatostatin may inhibit an inhibitory system involved in 
thirst (114), we suggested that somatostatin may suppress a tonic, GABAergic inhibition o f  
angiotensinergic neurons (90). GABA inhibits the dipsogenic, pressor and vasopressin
responses o f angiotensin II (115) whereas somatostatin releases these activities by inhibiting 
GABAergic transmission. Our findings do not exclude the possibility that hypothalamus 
angiotensin may also stimulate a particular subset o f somatostatinergic neurons which 
modulate sodium appetite (114).
Vasopressin content o f the hypothalamus was not altered significantly by icv injection of 
octreotide while octreotide elicited immediate decrease in vasopressin content o f the pituitary. 
This decrease is in agreement with previous experiments reporting significant rises in the 
plasma level o f vasopressin as soon as 5 min after icv somatostatinergic stimulation (90,116). 
Hypothalamic magnocellular neurons are the source o f pituitary vasopressin (117). It was 
anticipated, therefore, that vasopressin secretion can also be detected as a drop in 
hypothalamic vasopressin contents. One and 3 h after octreotide injection, mean hypothalamic 
vasopressin content were in fact lower than in the control rats but these changes were not 
significant. On the one hand, vasopressin is stored in the nerve terminals o f posterior pituitary, 
and thus vasopressin release may occur without significant alterations in hypothalamic 
vasopressin. On the other hand, vasopressin is also found in hypothalamic neurons (mainly in 
the suprachiasmatic nucleus), which do not project to the pituitary. Therefore, determination 
of total vasopressin contents o f the hypothalamus may not accurately reflect the activity o f the 
magnocellular neurons.
4.3 GHRH signaling in dw/dw rats
Hypothalamic GHRH mRNA levels were normal but GHRH content was significantly less in 
the dw/dw rats than in intact Lewis rats. The decreased hypothalamic GHRH content is 
interpreted as a sign o f enhanced GHRH release due to a failure o f the GH-mediated negative 
feedback. This interpretation is supported by earlier data. In vitro observations suggest that 
the release o f GHRH is enhanced in the dw/dw  rats (118). Depletion o f GHRH is observed in 
rats and mice with various GH deficiencies (119,120) and in rats after hypophysectomy 
(121,122).
GHRH receptor mRNA significantly decreased in the pituitary o f dw/dw  rats (55,123). A 
short and a long GHRH receptor mRNA species described in the rat pituitary (38,39). The 
short isoform is the predominant transcript and a shorter (a) and a longer (p) subtype o f this 
isoform have been distinguished (55).
GHRH receptor mRNA is expressed in the rat hypothalamus (52). Our results support this 
finding and it seems that the short GHRH receptor mRNA isoform is also the dominant in the 
hypothalamus/preoptic region. The significantly decreased GHRH receptor mRNA levels in 
the dw/dw rats indicate that the GHRH signaling mechanism has the same defect in the 
hypothalamus/preoptic region as the previously described deficit in the pituitary o f this strain 
o f rats.
The dw/dw rats spend less time in NREMS (light and dark period) and REMS (light period) 
than do the control Lewis rats. GHRH promotes NREMS by targeting neurons in the preoptic 
region (67,80). Decreases in central GHRHergic transmission may explain the permanent 
NREMS loss in the dw/dw rat secondary to GHRH receptor deficiency.
We could not detect GHRH binding in eight pools o f pituitaries o f dwarf rats, and it was weak 
in one pool. The extent o f this reduction in binding was at least moderately greater than the 
decrease in the levels o f GHRH receptor mRNA determined by us (Paper #3), and in other 
studies (55,123). Disperate changes in GHRH binding and GHRH mRNA, have been 
observed previously also by others (124). The reductions in GHRH receptor binding and 
mRNA may reflect somatotroph hypoplasia in the dw/dw  rat pituitary (97). Decrease in 
GHRH receptor mRNA may also be a consequence o f a defect in GHRH signaling. For 
example, decreased binding o f GHRH to GHRH receptors may decrease GHRH-induced 
promotion o f further GHRH receptor synthesis. Alterations in translation o f GHRH receptor 
mRNA can also decrease receptor protein synthesis. Mutations o f proteins, which mediate the 
function o f a particular receptor, may also alter binding (39). In conclusion, in addition to the 
possible defects in GHRH receptor transcription or a failure o f the signal transduction 
mechanism, translational and/or posttranslational modifications o f the GHRH receptor should 
also be considered as potential causes o f the GH deficiency in the dw/dw  rat.
4.4 Effects o f  sleep deprivation on hypothalamic and pituitary GHRH receptors 
Both GHRH binding and GHRH receptor mRNA levels decreased in the hypothalamus after 
sleep deprivation, whereas there were no alterations in the pituitary. We detected a single 
class o f GHRH binding sites in the hypothalamus with a much lower affinity than GHRH 
binding sites o f the pituitary. Specific high affinity binding sites for GHRH have been 
reported on pituitary membranes (33,125,126). GHRH binding sites are also found in human 
cancer cells (59,127), in the rat renal medulla (125), in the granulosa cells o f the ovary (25),
but they possess different characteristics from binding sites in the pituitary. Intrahypothalamic 
GHRH binding also clearly differed from GHRH binding in the rat pituitary. The GHRH 
binding sites in the hypothalamus displayed a similar affinity for VIP than for GHRH. GHRH 
is a member o f the secretin-glucagon peptide family, and cross-reactivity is often observed 
between receptors for individual peptides in the family. VIP receptors display significant 
GHRH binding (128). However, it is unlikely that the GHRH binding sites in our 
hypothalamic samples are VIP receptors, because the affinity o f the VIP receptors is much 
higher for VIP than for GHRH in the brain (129) and other tissues (130,131). A special 
binding site, coined the VIP/GHRH receptor, has been described in granulosa cells o f the 
ovary, on which both VIP and GHRH act as physiological ligands (25). The hypothalamic 
binding sites found in our experiments might be similar to those receptors.
Hypothalamic GHRH receptor mRNA decreased to the same extent as GHRH binding after 
sleep deprivation. It is an important observation suggesting that the hypothalamic binding 
sites function as GHRH receptors. The primers used for determining GHRH receptor mRNA 
in the hypothalamus detect the major functional GHRH receptor mRNA in the pituitary (126). 
Tumor cells (59,127) and also pituitary (126) express splice variants o f the GHRH receptors. 
It is possible, therefore, that the different binding characteristics o f  pituitary and hypothalamic 
GHRH receptors may result from alternative splicing o f the mRNA.
Hypothalamic GHRH is implicated in physiological sleep regulation and in sleep responses to 
sleep deprivation (132). Our data suggest an approximately 50% down-regulation of 
hypothalamic GHRH receptors after 8 h o f sleep deprivation and the number o f receptors does 
not seem to recover within the first 2 h upon completion o f sleep deprivation. Prolonged 
GHRH exposure down-regulate GHRH receptors in the pituitary (133). Sleep deprivation 
causes significant GHRH release resulting in a robust GHRH depletion by the end o f 8 h o f 
sleep deprivation, and the GHRH release is likely continue during recovery sleep (Paper #1). 
The changes in GHRH binding and GHRH receptor mRNA levels o f  the hypothalamus, 
therefore, are consistent with a sleep deprivation-associated GHRH release.
CONCLUSIONS
Comparisons o f the variations in hypothalamic GHRH contents with previously reported 
changes in GHRH mRNA levels o f the hypothalamus suggest that the time o f the day where 
maximum GHRH synthesis and release occur corresponds to the period o f deepest NREMS. 
Experiments with sleep deprivation support this conclusion showing that sleep deprivation for 
8 h results in excessive depletion o f hypothalamic GHRH with very low GHRH contents at 
the termination o f the deprivation. Another finding that indirectly supports an excessive 
GHRH release induced by sleep deprivation, is a 50% reduction o f GHRH binding and 
GHRH mRNA in the hypothalamus after 8 h o f sleep deprivation. It is characteristic o f  
GHRH receptors that massive exposure to GHRH elicits down-regulation, therefore, a robust 
intrahypothalamic GHRH release during and after sleep deprivation is a likely explanation for 
the down-regulation o f hypothalamic GHRH receptors.
The somatostatin analog, octreotide, promptly inhibits hypothalamic GHRH release 
coinciding with sleep suppression. After 1-3 h postinjection, when intensity o f NREMS 
increases, the accumulated GHRH is gradually released from the hypothalamus. Therefore, a 
possible explanation for the biphasic sleep response to octreotide is that octreotide suppresses 
sleep via inhibiting GHRH release, and this period is followed by supranormal GHRH release 
and resulting in deep NREMS. In addition, our experiments revealed, that somatostatin may 
also be involved in the control o f intracerebral angiotensinergic system regulating water 
balance.
The dwarf (dw/dw) rats exhibit both intracerebral and pituitary deficits in GHRH receptors 
and they sleep less than the normal Lewis rats. These results suggest that somatotropic 
functions and sleep regulation are intimately related.
Our results demonstrate that GHRH receptors exist in the hypothalamus and they respond 
differently to sleep deprivation than the GHRH receptors in the pituitary.
These observations support the hypothesis that hypothalamic GHRH has a major role in the 
physiological regulation o f sleep.
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SUMMARY
Sleep is regulated by interdependent humoral and neuronal mechanisms. The somatotropic 
axis is a major hormone system that influences sleep-wake activity. Hypothalamic GHRH is 
one o f the best documented sleep-promoting substance. Somatostatin mediates negative 
feedback in the somatotropic axis by inhibiting both GHRH and GH. The aim o f our work 
was to extend our knowledge on the interaction between GHRH and sleep including 
experiments to a; determine o f hypothalamic GHRH content in correlation with sleep, after 
somatostatinergic stimulation, and in chronic somatotropic deficiency, b; characterize 
hypothalamic and pituitary GHRH receptors in the dwarf rats, and after sleep deprivation. 
Results: a; GHRH peptide contents in the hypothalamus display diurnal variations that 
correlate with sleep-wake activity, and respond to sleep deprivation. These changes suggest 
enhanced GHRH release during the period of deep NREMS, i.e., during the first portion o f the 
diurnal rest period and during recovery sleep after sleep deprivation. Intense GHRH release, 
however, starts already during sleep deprivation. Hypothalamic somatostatin contents also 
vary across the 24-h day, but sleep deprivation does not appreciably alter the total 
somatostatin content o f the hypothalamus. The somatostatin analog, octreotide, causes a rise 
in GHRH content o f the hypothalamus 1 h post-injection followed by a (1-6 h) gradual 
depletion o f accumulated GHRH. During our experiments with icv-administered octreotide, 
we observed prompt drinking behavior. The serendipitous observation prompted additional 
studies regarding its underlying mechanism. Hypothalamic angiotensin II decreases promptly 
after octreotide treatment, while vasopressin content o f the hypothalamus is not altered. 
Hypothalamic GHRH content is less in the dw/dw rats than in normal Lewis rats, b; Pituitary 
GHRH binding is almost abolished and both pituitary and hypothalamic GHRH receptor 
mRNA are decreased in the dw/dw  rats. GHRH binding and GHRH receptor mRNA levels are 
reduced in the hypothalamus o f sleep-deprived rats, whereas there are no alterations in the 
pituitary. Conclusions: Sleep-related changes in hypothalamic GHRH contents and GHRH 
receptors suggest enhanced GHRH release during the period o f deep NREMS, i.e., during the 
first portion o f the diurnal rest period and during recovery sleep after sleep deprivation. The 
octreotide-induced alterations in hypothalamic GHRH may explain previously reported 
changes in sleep. Our experiments suggest that angiotensin may mediate octreotide-induced 
drinking, vasopressin secretion and rises in blood pressure via sst2 receptors. The present 
findings provide evidence for a deficit in GHRH receptors in both hypothalamus and pituitary
of the dw/dw rats. These mutant rats sleep less, therefore, our results support that GHRH 
involved in sleep regulation.
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